Enanta Pharmaceuticals (ENTA) Equity Average (2013 - 2026)

Enanta Pharmaceuticals (ENTA) has 14 years of Equity Average data on file, last reported at $121.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 18.42% year-over-year to $121.6 million; the trailing twelve-month figure through Mar 2026 stood at $121.6 million (up 18.42% YoY), and the FY2025 full-year result was $96.8 million, down 43.99% from the prior year.
• Equity Average for Q1 2026 stood at $121.6 million, up from $95.7 million in the prior quarter.
• Across five years, Equity Average topped out at $371.5 million in Q1 2022 and bottomed at $72.0 million in Q3 2025.
• The 5-year median for Equity Average is $179.0 million (2024), against an average of $200.3 million.
• The widest annual swing landed in 2025, when Equity Average sank 48.15%; it then gained 18.42% in 2026.
• A 5-year view of Equity Average shows it stood at $311.1 million in 2022, then plunged by 34.32% to $204.3 million in 2023, then tumbled by 41.11% to $120.3 million in 2024, then retreated by 20.5% to $95.7 million in 2025, then increased by 27.11% to $121.6 million in 2026.
• The last three Equity Average figures came in at $121.6 million (Q1 2026), $95.7 million (Q4 2025), and $72.0 million (Q3 2025), per Business Quant data.

Peer Comparison